James Treace - Apr 28, 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for James T. Treace
Stock symbol
TMCI
Transactions as of
Apr 28, 2023
Transactions value $
-$1,252,695
Form type
4
Date filed
5/2/2023, 09:00 PM
Previous filing
Mar 31, 2023
Next filing
May 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$1M -40K -4.39% $25.01 871K Apr 28, 2023 Direct F1, F2
transaction TMCI Common Stock Sale -$191K -7.64K -0.88% $25.04 864K May 1, 2023 Direct F1, F3
transaction TMCI Common Stock Sale -$61.1K -2.36K -0.27% $25.91 861K May 1, 2023 Direct F1, F4
holding TMCI Common Stock 556K Apr 28, 2023 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.4100 to $25.3050 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5400 to $25.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5400 to $26.1500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.